State Action
CCAGW Urges Kentucky Senate Appropriations and Revenue Committee to Oppose HB 457
HB 457 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers.
CCAGW Urges Missouri House of Representatives to Oppose HB 1677
HB 1677 would create unnecessary regulatory barriers that will undermine the effectiveness of pharmaceutical benefit managers.
CCAGW Urges Alaska House Judiciary Committee to Oppose HB 159
HB 159 will fail to achieve its objective to protect consumer privacy.
CCAGW Urges Colorado House Health and Insurance Committee to Oppose HB 1064
HB 1064 would band the sale of all flavored nicotine products including e-cigarettes.
CCAGW Urges Connecticut Committee on Insurance and Real Estate to Oppose SB 355
SB 355 fails to solve longstanding problems and institutes heavy-handed government mandates which result in market distortion and price controls.
CCAGW Urges West Virginia Health and Human Resources Committee to Oppose HB 4112
HB 4112 would impose onerous regulations on pharmacy benefit management and interfere with privately negotiated contracts among insurers, pharmaceutical benefit managers (PBM), and the sponsors they serve
CCAGW Urges Maine Joint Energy Utilities And Technology Committee to Oppose SB 1894
SB 1894 incentivizes and prioritizes government-owned networks over private or public/private partnerships for funding from the state’s Internet Access Expansion Investment Fund.
CCAGW Urges Connecticut General Assembly Joint General Law Committee to Oppose SB 6
SB 6 will fail to achieve its objective to protect consumer privacy.
CCAGW Urges Washington House Appropriations Committee to Oppose HB 5532
SB 5532 would institute harmful price controls that would cause the loss of jobs and damage to Washington's economy.
CCAGW Urges Washington House Appropriations Committee to Oppose HB 1850
HB 1850 will fail to achieve its objective to protect consumer privacy.
CCAGW Urges Utah House Labor and Commerce Committee to Oppose HB 308
HB 308 would institute a manufacturer mandate, which constitutes a government price control, thus further distorting the medical marketplace.
CCAGW Urges Mississippi Senate Leadership to Oppose HB 733
H.B. 733 will make changes to the federal 340B drug program.
